In my view, there is nothing really new for us in these two case reports, but they might still be interesting. Below is the abstract, and attached the article.
Best,
Johannes
Treatment of Metastatic, Refractory Alveolar Soft Part Sarcoma: Case Reports and Literature Review of Treatment Options in the Era of Targeted Therapy.
J Pediatr Hematol Oncol. 2016 Jul;38(5):e169-72. doi: 10.1097/MPH.0000000000000571.
http://www.ncbi.nlm.nih.gov/pubmed/27164526
Kuo DJ1, Menell JS, Glade Bender JL.
BACKGROUND:
Alveolar soft part sarcoma is a rare soft tissue sarcoma that is characterized by a pattern of slow growth with metastases to the lung, bone, and brain that is not responsive to conventional cytotoxic chemotherapy.
OBSERVATIONS:
We describe 2 patients, with a combined 19 years of treatment experience including multiple different chemotherapeutic and targeted therapy regimens, surgery, and radiotherapy. We also present a review of the literature regarding treatment options to highlight recent findings.
CONCLUSIONS:
Alveolar soft part sarcoma is an indolent, but persistently progressive disease. Novel therapeutic agents hold promise in its management.
Two ASPS cases reported in J Pediatr Hematol Oncol in July 2016
Two ASPS cases reported in J Pediatr Hematol Oncol in July 2016
- Attachments
-
- Kuo et al - Treatment of Metastatic, Refractory Alveolar Soft Part Sarcoma 2016.pdf
- (117.43 KiB) Downloaded 142 times
Re: Two ASPS cases reported in J Pediatr Hematol Oncol in July 2016
Thank you for posting this article as i found few very surprising details there:
- both patients had very significant period of stability on sorafenib alone (22 months each) and rapamycin and sorafenib again (1 year), that includes their brain metastases. the doctors were pretty clever not to discontinue this drug after a progression in a single nodule but just resecting it and continue with the active drug till more wide progression. We did not consider sorafenib an active drug for ASPS, so it is a very good and important news as it is widely available and can be prescribed for ASPS based on this published report. I will repost it in the TKI topic.
And once again it was demonstrated that there is a very significant difference in the response of the mets depends on the location, some respond when some do not and they need to be treated locally (ablated, resected, Gammaknife-ed).
- both patients had very significant period of stability on sorafenib alone (22 months each) and rapamycin and sorafenib again (1 year), that includes their brain metastases. the doctors were pretty clever not to discontinue this drug after a progression in a single nodule but just resecting it and continue with the active drug till more wide progression. We did not consider sorafenib an active drug for ASPS, so it is a very good and important news as it is widely available and can be prescribed for ASPS based on this published report. I will repost it in the TKI topic.
And once again it was demonstrated that there is a very significant difference in the response of the mets depends on the location, some respond when some do not and they need to be treated locally (ablated, resected, Gammaknife-ed).
Olga